Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT02576522 Completed - Brain Metastases Clinical Trials

Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor

Start date: June 29, 2015
Phase: N/A
Study type: Interventional

Investigators designed a study of a multimodality approach: surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach for patients with single, large brain metastases from solid primary tumor

NCT ID: NCT02575521 Completed - Surgery Clinical Trials

Effect of Propofol-Dexmedetomidine on Cerebral Oxygenation and Metabolism During Brain Tumor Resection

Start date: August 2015
Phase: N/A
Study type: Interventional

Despite theoretical benefits of intravenous agents, volatile agents remain popular. In a study comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial hypertension, at equipotent doses and normocapnia, cerebral blood flow (CBF) and intra-cranial pressure (ICP) were least with sevoflurane. Propofol is the most commonly used intravenous anesthetic. It has many theoretical advantages by reducing cerebral blood volume (CBV) and ICP and preserving both autoregulation and vascular reactivity. Neurosurgical patients anaesthetized with propofol were found to have lower ICP and higher CPP than those anaesthetized with isoflurane or sevoflurane. The well known pharmacodynamic advantages of intravenous anesthetics may give this group of drugs superior cerebral effects when compared with inhalation anesthetics.

NCT ID: NCT02575027 Completed - Glioblastoma Clinical Trials

Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Start date: November 12, 2014
Phase: N/A
Study type: Interventional

This pilot clinical trial studies the feasibility of palliative 4pi radiotherapy in treating patients with glioblastoma multiforme that has come back after standard chemoradiation. A new radiotherapy delivery planning system, called 4pi radiotherapy, may help improve radiation delivery by improving dose coverage to the treatment target, while reducing the dose to surrounding normal tissues.

NCT ID: NCT02558569 Completed - Brain Tumor Clinical Trials

The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block

Start date: September 2015
Phase: Phase 4
Study type: Interventional

This study evaluates the use of fentanyl during craniotomy in two groups of brain tumor patients. The control group will receive standard general anesthesia with the use of fentanyl for intraoperative pain control and the study group will receive scalp nerve block with 0.5% levobupivacaine (local anesthetic) and also fentanyl for intraoperative pain control. The scalp nerve block might reduce the dose of fentanyl and promote faster emergence from general anesthesia.

NCT ID: NCT02537106 Completed - Brain Tumors Clinical Trials

A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation

Start date: September 2015
Phase: N/A
Study type: Interventional

Hyperosmotic solutions of 1.5% and 3% NaCl are equally effective for brain relaxation and microcirculation during brain surgery. The effect of 1.5% NaCl on postoperative natremia and natriuresis is less pronounced.

NCT ID: NCT02530749 Completed - Brain Tumors Clinical Trials

Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients

Start date: April 2014
Phase:
Study type: Observational

Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current perioperative risk models.

NCT ID: NCT02514915 Completed - Clinical trials for Malignant Neoplasm Brain

Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases

Start date: December 1, 2016
Phase: N/A
Study type: Interventional

The primary goal of this research study is to determine the efficacy of giving pre-operative radiosurgery to patients pending resection of a brain metastasis.

NCT ID: NCT02505165 Completed - Lymphoma Clinical Trials

Illness Management and Parental Adjustment to Cancer Treatment

IMPACT
Start date: November 19, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to test the efficacy of a clinic-based intervention designed to reduce illness uncertainty for parents of children who have been recently diagnosed with cancer.

NCT ID: NCT02502708 Completed - Glioma Clinical Trials

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Start date: October 2015
Phase: Phase 1
Study type: Interventional

This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors. Using a preclinical glioblastoma model, it was recently shown that adding IDO-blocking drugs to temozolomide plus radiation significantly enhanced survival by driving a vigorous, tumordirected inflammatory response. This data provided the rationale for the companion adult phase 1 trial using indoximod (IND#120813) plus temozolomide to treat adults with glioblastoma, which is currently open (NCT02052648). The goal of this pediatric study is to bring IDO-based immunotherapy into the clinic for children with brain tumors. This study will provide a foundation for future pediatric trials testing indoximod combined with radiation and temozolomide in the up-front setting for patients with newly diagnosed central nervous system tumors.

NCT ID: NCT02489071 Completed - Brain Tumors Clinical Trials

Cognitive Intervention After a Brain Tumor

Start date: August 2014
Phase: N/A
Study type: Interventional

This study evaluates the feasibility and utility of two behavioural programs designed to reduce cognitive impairments secondary to brain tumors and/or their treatment. One-third of participants will complete training in either program, with the remaining third a wait-list control group.